Serina Therapeutics (SER) Cost of Revenue (2018 - 2023)

Serina Therapeutics has reported Cost of Revenue for 6 years, with the latest figure at $1000.0 in Q4 2023.

• Quarterly Cost of Revenue changed 0.0% year-over-year to $1000.0 in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $40000.0 (up 207.69% YoY) and the FY2023 annual result came in at $40000.0, up 207.69% from the prior year.
• Cost of Revenue slipped to $1000.0 in Q4 2023 per SER's latest filing, from $33000.0 in the prior quarter.
• Over five years, Cost of Revenue peaked at $79000.0 in Q4 2019 and troughed at $1000.0 in Q1 2020.
• A 5-year average of $17100.0 and a median of $5000.0 in 2020 frame the typical range for Cost of Revenue.
• The sharpest annual moves came in 2019 and 2020: Cost of Revenue soared 1125.0% in 2019, then plunged 98.41% in 2020.
• Over 5 years, Cost of Revenue stood at $79000.0 in 2019, then plunged by 93.67% to $5000.0 in 2020, then tumbled by 80.0% to $1000.0 in 2021, then changed by 0.0% to $1000.0 in 2022, then changed by 0.0% to $1000.0 in 2023.
• According to Business Quant data, Cost of Revenue over the past three periods registered $1000.0, $33000.0, and $5000.0 for Q4 2023, Q3 2023, and Q2 2023 respectively.